You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 8,802,624


✉ Email this page to a colleague

« Back to Dashboard


Title:Methods of treatment using orodispersible desmopressin pharmaceutical formulations
Abstract: Described herein are methods of treating diseases or conditions such as incontinence, primary nocturnal enuresis (PNE), nocturia, and central diabetes insipidus, by administering desmopressin acetate in an orodispersiblc solid dosage form that disintegrates in the mouth within 10 seconds and includes an amount of desmopressin acetate, measured as the free base, of from 10 to 600 .mu.g.
Inventor(s): Nilsson; Anders (Lund, SE), Lindner; Hans (Leichlingen, DE), Wittendorff; Jorgen (Hvidovre, DK)
Assignee: Ferring B.V. (Hoofddorp, NL)
Filing Date:May 18, 2011
Application Number:13/110,619
Claims:1. A method of treating a disease or condition selected from the group consisting of incontinence, primary nocturnal enuresis (PNE), nocturia, and central diabetes insipidus, comprising administering to a subject an effective and generally non-toxic amount of desmopressin acetate in an orodispersible solid dosage form, wherein said dosage form (A) disintegrates in the mouth within 10 seconds and (B) comprises an amount of desmopressin acetate, measured as the free base, of from 10 to 600 .mu.g.

2. The method of claim 1, wherein the disease or condition is primary nocturnal enuresis (PNE).

3. The method of claim 1, wherein the disease or condition is nocturia.

4. The method of claim 1, wherein the dosage form comprises an open matrix network carrying the desmopressin acetate, the open matrix network being comprised of a water-soluble or water-dispersable carrier material that is inert towards desmopressin.

5. The method of claim 4, wherein the open matrix network comprises gelatin.

6. The method of claim 5, wherein the gelatin is fish gelatin.

7. The method of claim 6, wherein the fish gelatin is non-gelling.

8. The method of claim 1, wherein the dosage form disintegrates in the mouth within 5 seconds.

9. The method of claim 1, wherein the dosage form disintegrates in the mouth within 2 seconds.

10. The method of claim 1, wherein the dosage form disintegrates in the mouth within 1 second.

11. The method of claim 1, wherein the dosage form is administered once per day.

12. The method of claim 1, wherein the dosage form is administered twice per day.

13. The method of claim 1, wherein the method achieves a maximum plasma concentration of desmopressin in about 0.5-2 hours after administration.

14. The method of claim 1, wherein the method achieves a mean elimination half-life of desmopressin of about 2.8-3 hours after the maximum plasma concentration is reached.

15. The method of claim 1, wherein the method achieves a linear pharmacokinetics of desmopressin.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.